ABVX Abivax SA

EQS-News: ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT

EQS-News: ABIVAX / Key word(s): Half Year Results
ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT

30.09.2022 / 18:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT

PARIS, France, September 30, 2022 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publication of its 2022 half-year financial report.

This document is available in electronic version on the website of the company () and on the website of the French financial markets authority, AMF ().

*****

About Abivax ()

Abivax, a phase 3 clinical stage biotechnology company, is developing novel therapies that modulate the body’s natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, obefazimod (ABX464) to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at . Follow us on Twitter @ABIVAX_.

Contacts

Abivax                 
Communications
Regina Jehle

63		 Investors
LifeSci Advisors
Ligia Vela-Reid

 Press Relations & Investors Europe
MC Services AG
Anne Hennecke

22
Public Relations France
Actifin
Ghislaine Gasparetto

24		 Public Relations France
Primatice
Thomas Roborel de Climens

95		 Public Relations USA     
Rooney Partners LLC
Jeanene Timberlake

30.09.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com

1454659  30.09.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1454659&application_name=news&site_id=research_pool
EN
30/09/2022

Underlying

ABVXAbivax SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abivax SA

Juan Ros-Padilla
  • Juan Ros-Padilla
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
NK IMERYS SA
AUTN AUTONEUM HOLDING AG
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
BFIT BASIC-FIT NV
GTT GAZTRANSPORT & TECHNIGAZ SA
SSAB A SSAB AB CLASS A
RCO REMY COINTREAU SA
TFI TELEVISION FRANCAISE 1 SA
KORI KORIAN SA
SZG SALZGITTER AG
ABVX ABIVAX SA
OERL OC OERLIKON CORPORATION AG
CDA COMPAGNIE DES ALPES SA
ALTA ALTAREA SCA
VOE VOESTALPINE AG
ACX ACERINOX SA
EBRO EBRO FOODS SA
SOLB SOLVAY SA
NEX NEXANS SA
ERA ERAMET SA
COR CORTICEIRA AMORIM SGPS SA
NDA AURUBIS AG
KRN KRONES AG
PAL PALFINGER AG
ROYAL VOPAK NV
MMT METROPOLE TELEVISION SA
AED AEDIFICA SA
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
SEFER SERGEFERRARI GROUP SA
WAF SILTRONIC AG
MELE MELEXIS NV
ZAG ZUMTOBEL GROUP AG
TWEKA TKH GROUP N.V. CERT
WLN WORLDLINE SA
IBG IBERPAPEL GESTION S.A.
PSG PROSEGUR COMPANIA DE SEGURIDAD SA
RIO RIO TINTO PLC
UNI UNICAJA BANCO S.A.
BHP BHP GROUP LTD
SMCP SMCP SA
BFSA BEFESA SA
AMAG AMAG AUSTRIA METALL AG
THEP THERMADOR HOLDING SA
VRLA VERALLIA SAS
GRP GREENCOAT RENEWABLES
SFQ SAF-HOLLAND SE
VUL VULCAN ENERGY RESOURCES
AG1 AUTO1 GROUP
EAPI EUROAPI
BRE BREMBO S.P.A.
EXENS EXOSENS
CO CASINO GUICHARD-PERRACHON
HAVAS HAVAS N.V
CAN CANAL+
HBX HBX GROUP INTERNATIONAL PLC
AAL ANGLO AMERICAN PLC
07/30/25 July 30, 2025 1 EN
Juan Ros-Padilla
  • Juan Ros-Padilla
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
NK IMERYS SA
AUTN AUTONEUM HOLDING AG
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
BFIT BASIC-FIT NV
GTT GAZTRANSPORT & TECHNIGAZ SA
SSAB A SSAB AB CLASS A
RCO REMY COINTREAU SA
TFI TELEVISION FRANCAISE 1 SA
KORI KORIAN SA
SZG SALZGITTER AG
ABVX ABIVAX SA
OERL OC OERLIKON CORPORATION AG
CDA COMPAGNIE DES ALPES SA
ALTA ALTAREA SCA
VOE VOESTALPINE AG
ACX ACERINOX SA
EBRO EBRO FOODS SA
SOLB SOLVAY SA
NEX NEXANS SA
ERA ERAMET SA
COR CORTICEIRA AMORIM SGPS SA
NDA AURUBIS AG
KRN KRONES AG
PAL PALFINGER AG
ROYAL VOPAK NV
MMT METROPOLE TELEVISION SA
AED AEDIFICA SA
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
SEFER SERGEFERRARI GROUP SA
WAF SILTRONIC AG
MELE MELEXIS NV
ZAG ZUMTOBEL GROUP AG
TWEKA TKH GROUP N.V. CERT
WLN WORLDLINE SA
IBG IBERPAPEL GESTION S.A.
PSG PROSEGUR COMPANIA DE SEGURIDAD SA
RIO RIO TINTO PLC
UNI UNICAJA BANCO S.A.
BHP BHP GROUP LTD
SMCP SMCP SA
BFSA BEFESA SA
AMAG AMAG AUSTRIA METALL AG
THEP THERMADOR HOLDING SA
VRLA VERALLIA SAS
GRP GREENCOAT RENEWABLES
SFQ SAF-HOLLAND SE
VUL VULCAN ENERGY RESOURCES
AG1 AUTO1 GROUP
EAPI EUROAPI
BRE BREMBO S.P.A.
EXENS EXOSENS
CO CASINO GUICHARD-PERRACHON
HAVAS HAVAS N.V
CAN CANAL+
HBX HBX GROUP INTERNATIONAL PLC
AAL ANGLO AMERICAN PLC
07/30/25 July 30, 2025 1 FR
Martial Descoutures
  • Martial Descoutures
ABVX ABIVAX SA

Abivax : A well-deserved success, Outperform confirmed

We are significantly raising our TP from € 24 to € 88 following the positive results of the phase 3 induction trial (ABTECT) for obefazimod in ulcerative colitis. Obefazimod achieved significant clinical remission rates higher than those observed in phase 2b, and comparable to the best agents under development. Based on these results, we believe that Abivax is a credible M&A target for a pharma player looking to strengthen its position in immunology. Outperform rating reiterated.

07/29/25 July 29, 2025 1 EN
Martial Descoutures
  • Martial Descoutures
ABVX ABIVAX SA

Abivax : Un succès bien mérité, Surperformance confirmée

Nous relevons significativement notre OC de 24 € à 88 € suite aux résultats positifs de la phase 3 (ABTECT) en induction d’obefazimod dans la rectocolite hémorragique. Obefazimod a atteint des taux de rémission clinique significatifs supérieurs à ceux observés en phase 2b, et comparables aux meilleurs agents en développement. Suite à ces résultats, nous croyons qu’Abivax est une cible crédible d’acquisition pour une Pharma voulant se renforcer en Immunologie. Recommandation Surperformance réitér...

07/29/25 July 29, 2025 1 FR
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Announces Closing of $747.5 Million Public Offering

Abivax Announces Closing of $747.5 Million Public Offering Abivax Announces Closing of $747.5 Million Public Offering PARIS, France, July 28, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the closing of its previously announced underwritten public offering of 11,679,400 American Depositary Shares (“ADSs”), each r...

July 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch